19972021
If you made any changes in Pure these will be visible here soon.

Personal profile

Scholarly biography

Andrew Lloyd graduated from Robinson College, University of Cambridge in 1986 with a degree in Natural Sciences, specialising in bioorganic chemistry, biochemistry and pharmacology. He completed his PhD in biopharmaceutics and was appointed to the academic staff in the Department of Pharmacy, University of Brighton as a Lecturer in Pharmaceutical Sciences in 1989, and was promoted to Senior Lecturer in 1993. He was made Reader in Biopharmaceutical Sciences and elected to Fellowship of the Royal Society of Chemistry in 1998 and promoted to the chair in Biomedical Materials in 2000. He was appointed as Joint Head of Research with responsibility for strategic planning in the School of Pharmacy & Biomolecular Sciences in 2000, Dean of the Faculty of Science & Engineering in 2003, Dean of the College of Life, Health & Physical Sciences in 2014 and Associate Pro-Vice-Chancellor (Academic Operations) in July 2017. He was interim Pro-Vice-Chancellor (Research & Enterprise) for 6 months in 2016, and appointed to his present role as Pro-Vice-Chancellor (Academic Operations) in October 2019.

He was awarded the University of Brighton Patani Gold Medal for Pharmaceutical Research in 1990, the University of Brighton Chairman’s Award for Innovation in 1996 and 2005, the Lilly Prize for Pharmaceutical Excellence in 1999, the Royal Pharmaceutical Society of Great Britain's (RPSGB) Conference Science Award in 2000, the United Kingdom Society for Biomaterials (UKSB) Biocompatibles’ Endowed Lectureship in 2005.

Professor Lloyd was the British Pharmaceutical Conference Science Chair in 2008. Andrew's primary research interests include the development and evaluation of novel materials for drug delivery and medical device applications.  At present his research focuses on the development of novel medical materials which offer improved performance in the body in order to reduce the costs of primary healthcare. His research has been funded by EPSRC, BBSRC, NHS, Royal Society, European Union and various international pharmaceutical and medical device companies. He has published over 300 articles and was formerly Consultant Editor for 'Drug Discovery Today' and 'Pharmaceutical Science & Technology Today' and co-edited of the undergraduate textbook ‘Drug Delivery & Targeting for Pharmacists and Pharmaceutical Scientists’.

Professor Lloyd previously served as a Member of the Council for the UK Society for Biomaterials, Member of the Institute of Materials, Mining and Mineralogy Biomedical Division Biomaterials Committee, Member of the RSC Biomaterials Chemistry Group Committee and is presently a member of the EPSRC Peer-review Council. He also serves on the editorial boards of Journal of Applied Biomaterials and Biomechanics (JABB) and Expert Review of Medical Devices.

Professor Lloyd acts in an advisory capacity for a number of pharmaceutical and medical device companies and was formerly a director of a small biotechnology company 'Cellective Ltd', which undertook contract research related to in vitro drug adsorption and the assessment of the biological compatibility of biomedical material.

Supervisory Interests

Supervisory research interests include the synthesis and evaluation of novel polymeric materials for drug delivery, medical device and other applications including contact lens technology, chemoembolisation systems and bioresponsive oral drug delivery systems. I am also interested in the application of chemical sciences to understanding and solving environmental and societal challenges.

Research interests

  • The synthesis and evaluation of novel polymeric materials for drug delivery, medical device and other applications including contact lens technology, chemoembolisation systems and bioresponsive oral drug delivery systems.
  • The application of chemical sciences to understanding and solving environmental and societal challenges.

Education/Academic qualification

Master, University of Cambridge

1990

Bachelor, University of Cambridge

1 Oct 198330 Jun 1986

PhD, University of Brighton

1 Sep 198631 Aug 1989

Fingerprint Dive into the research topics where Andrew Lloyd is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Bacterial Adhesion Medicine & Life Sciences
Carbon Chemical Compounds
Micelles Chemical Compounds
Adsorption Chemical Compounds
Biocompatible Materials Medicine & Life Sciences
Polymers Chemical Compounds
Polyurethanes Chemical Compounds
Phosphorylcholine Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2019 2021

Research Output 1997 2019

Possible mineral contributions to the diet and health of wild chimpanzees in three East African forests

Reynolds, V., Pascual ‐ Garrido, A., Lloyd, A., Lyons, P. & Hobaiter, C., 14 May 2019, In : American Journal of Primatology. 81, 6, p. 1-11 11 p., e22978.

Research output: Contribution to journalArticleResearchpeer-review

Pan troglodytes
termite mounds
diet
minerals
termite

Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods

Hagan, A., Caine, M., Press, C., Macfarlane, W., Phillips, G., Lloyd, A., Czuczman, P., Kilpatrick, H., Bascal, Z., Tang, Y., Garcia, P. & Lewis, A., 29 May 2019, In : European Journal of Pharmaceutical Sciences. 136, p. 1-24 24 p., 104943.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Pharmacokinetics
Pharmaceutical Preparations
irinotecan
Blood Vessels
Pulsatile Flow

Hypoxia as a target for drug combination therapy of liver cancer

Bowyer, C., Lewis, A., Lloyd, A., Phillips, G. & Macfarlane, W., 24 May 2017, In : Anti-Cancer Drugs. 28, 7, p. 771-780 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Liver Neoplasms
Combination Drug Therapy
Doxorubicin
Hypoxia-Inducible Factor 1
Hepatocellular Carcinoma

Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies

Hagan, A., Phillips, G., Macfarlane, W., Lloyd, A., Czuczman, P. & Lewis, A., 27 Jan 2017, In : European Journal of Pharmaceutical Sciences. 101, p. 22-30 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Liver
Pharmaceutical Preparations
Neoplasms
Protein-Tyrosine Kinases
X-Ray Emission Spectrometry

Towards Hypoxia-responsive Drug-eluting Embolization Beads

Ashrafi, K., Heaysman, C. L., Phillips, G., Lloyd, A. & Lewis, A., 31 Mar 2017, In : International Journal of Pharmaceutics. 254, 1-2, p. 226-237 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Cystine
Reducing Agents
Pharmaceutical Preparations
Doxorubicin
Spectroscopic analysis